{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:33:38Z","timestamp":1790674418015,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.antiviral.2019.104562","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T19:33:11Z","timestamp":1563305591000},"page":"104562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["New antibody-based prevention and treatment options for influenza"],"prefix":"10.1016","volume":"170","author":[{"given":"Koen","family":"Sedeyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104562_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104562_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104562_bib3","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104562_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104562_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080034","article-title":"Mechanisms of hemagglutinin targeted influenza virus neutralization","volume":"8","author":"Brandenburg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104562_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: a review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2019.104562_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005702","article-title":"Two escape mechanisms of influenza a virus to a broadly neutralizing stalk-binding antibody","volume":"12","author":"Chai","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.104562_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","article-title":"Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104562_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/JVI.02105-15","article-title":"Crystal structure of the conserved amino terminus of the extracellular domain of matrix protein 2 of influenza a virus gripped by an antibody","volume":"90","author":"Cho","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104562_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies","volume":"24","author":"Corti","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.104562_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"issue":"Supplement 1","key":"10.1016\/j.antiviral.2019.104562_bib12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/infdis\/jiz010","article-title":"Antibody determinants of influenza immunity","volume":"219","author":"Crowe","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"169","key":"10.1016\/j.antiviral.2019.104562_bib13","first-page":"5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"1950","author":"Dall'Acqua","year":"2002","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.antiviral.2019.104562_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40262-017-0564-y","article-title":"Pharmacokinetics of MHAA4549A, an anti-influenza a monoclonal antibody, in healthy subjects challenged with influenza a virus in a phase IIa randomized trial","volume":"57","author":"Deng","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2019.104562_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.104562_bib16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.antiviral.2019.104562_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.antiviral.2019.104562_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104562_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2019.104562_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"issue":"186","key":"10.1016\/j.antiviral.2019.104562_bib21","first-page":"1022","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection","volume":"1950","author":"El Bakkouri","year":"2011","journal-title":"J. Immunol. Baltim. Md"},{"issue":"11","key":"10.1016\/j.antiviral.2019.104562_bib22","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciy775","article-title":"Influenza vaccine effectiveness in the United States during the 2016-2017 season","volume":"68","author":"Flannery","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104562_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2019.104562_bib24","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0911806107","article-title":"Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses","volume":"107","author":"Grandea","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.104562_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104562_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.104562_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/emboj\/21.5.865","article-title":"H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes","volume":"21","author":"Ha","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.104562_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2019.104562_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104562_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41467-017-00928-3","article-title":"Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice","volume":"8","author":"He","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.104562_bib31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2019.104562_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2019.00098","article-title":"T and B Cell immune responses to influenza viruses in pigs","volume":"10","author":"Holzer","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2019.104562_bib33","first-page":"474","article-title":"Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants","volume":"4","author":"joint statement with the Fetus and Newborn Committee","year":"1999","journal-title":"Paediatr. Child Health"},{"key":"10.1016\/j.antiviral.2019.104562_bib34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza a subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104562_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.104562_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018","volume":"164","author":"Koszalka","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104562_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(85)90211-9","article-title":"Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface","volume":"40","author":"Lamb","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104562_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104562_bib39","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/nm.4224","article-title":"Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.104562_bib40","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/AAC.00607-16","article-title":"Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza a virus monoclonal antibody, MHAA4549A, in healthy volunteers","volume":"60","author":"Lim","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104562_bib41","first-page":"81","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers","volume":"50","author":"Mallory","year":"2017","journal-title":"Biol. J. Int. Assoc. Biol. Stand."},{"key":"10.1016\/j.antiviral.2019.104562_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104562_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/hv.8.1.18214","article-title":"Correlates of vaccine protection from influenza and its complications","volume":"8","author":"McCullers","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.antiviral.2019.104562_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference","volume":"149","author":"McKimm-Breschkin","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104562_bib45","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to influenza virus neuraminidase: an independent correlate of protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104562_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fimmu.2018.00865","article-title":"Therapeutic administration of broadly neutralizing FI6 antibody reveals lack of interaction between human IgG1 and pig Fc receptors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2019.104562_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chom.2013.06.004","article-title":"An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies","volume":"14","author":"Nakamura","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.104562_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/irv.12521","volume":"12","author":"Ng","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2019.104562_bib49","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104562_bib50","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.104562_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/jix292","article-title":"The hemagglutinin a stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses","volume":"216","author":"Paules","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104562_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.02.016","article-title":"Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection","volume":"141","author":"Pendzialek","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104562_bib53","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104562_bib54","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1128\/JVI.00119-10","article-title":"Influenza virus m2 ion channel protein is necessary for filamentous virion formation","volume":"84","author":"Rossman","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104562_bib55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2019.104562_bib56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.104562_bib57","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"10.1016\/j.antiviral.2019.104562_bib58","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1073\/pnas.1502374112","article-title":"A broadly neutralizing human monoclonal antibody is effective against H7N9","volume":"112","author":"Tharakaraman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.104562_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104562_bib60","first-page":"1","article-title":"Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico","author":"V\u00e1squez","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2019.104562_bib61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/jcm.25.3.559-562.1987","article-title":"Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum","volume":"25","author":"Wagner","year":"1987","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.104562_bib62","doi-asserted-by":"crossref","first-page":"16820","DOI":"10.1073\/pnas.1408605111","article-title":"Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity","volume":"111","author":"Wagner","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.104562_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2019.01.012","article-title":"Baloxavir marboxil in Japanese patients with seasonal influenza: dose response and virus type\/subtype outcomes from a randomized phase 2 study","volume":"163","author":"Watanabe","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104562_bib64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","article-title":"Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism","volume":"177","author":"Watanabe","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104562_bib65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza a outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2019.104562_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2019.104562_bib67","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/JVI.00078-15","article-title":"An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection","volume":"89","author":"Zanin","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104562_bib68","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/jvi.62.8.2762-2772.1988","article-title":"Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions","volume":"62","author":"Zebedee","year":"1988","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:50Z","timestamp":1759062590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421930258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":68,"alternative-id":["S016635421930258X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104562","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antibody-based prevention and treatment options for influenza","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104562"}}